Patent · US Active

Anti-huTNFR1 antibody and methods of use thereof for treatment

US8859739B2 · kind B2 · utility

17Cited by

1References

16Claims

0Family size

Assignee

BALIOPHARMA AG · CH

Inventors

Roland Kontermann · Jeffery Road, DE
Klaus Pfizenmaier · Tiefenbronn, DE
Andreas Herrmann · Stuttgart, DE
Kirstin Zettlitz · West Hollywood, US

Key dates

Filing date	Sep 16, 2011
Grant date	Oct 14, 2014
Priority date	—
Expiry date	Sep 16, 2031

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/92
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The disclosure to an anti-huTNFR1 antibody of the IgG1 type, which has a modified Fc region deficient in mediating effector function, a pharmaceutical preparation comprising such antibody, and an anti-huTNFR1 antibody of the IgG1 type for use as a TNF antagonist without forming an agonistic TNFR1 signalling complex, as an alternative to treatment with an anti-TNF therapeutic.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.